Exciva

Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT

20 January 2026 -- Heidelberg, Germany -- Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi...
Hauptstrasse 25, 69117 Heidelberg, Germany

+49 (0) 6221-6479990